BROADWOOD PARTNERS L.P. 13D and 13G filings for OncoCyte Corporation:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-04-07 10:38 am Purchase | 2023-04-03 | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS L.P. | 2,856,559 33.300% | 1,345,914 (+89.10%) | Filing |
| 2022-07-28 5:06 pm Purchase | 2022-07-21 | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS L.P. | 1,510,645 24.100% | 321,897 (+27.08%) | Filing |
| 2022-04-15 5:21 pm Purchase | 2022-04-13 | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS L.P. | 1,188,748 19.990% | 296,969 (+33.30%) | Filing |
| 2021-09-24 4:40 pm Unchanged | 2021-09-23 | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS L.P. | 891,780 19.300% | 0 (Unchanged) | Filing |
| 2021-02-09 5:10 pm Purchase | 2021-02-05 | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS L.P. | 891,780 20.100% | 30,000 (+3.48%) | Filing |
| 2021-01-22 4:18 pm Purchase | 2021-01-20 | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS L.P. | 861,780 21.600% | 253,911 (+41.77%) | Filing |